Biovica International AB (publ) (BIOVIC_B) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

and welcome to Bayer-Vika Q4 and full year presentation. My name is Anders Rulander, and I will be presenting together with the CFO, Anders Morén. And here's the agenda for the presentation. We'll start with a short introduction to Bayer-Vika, the company and the product. We'll go through the Q4 highlights, And then Anders will do the financial update. And then we will finally do a summary and open up for our Q&A session. During the Q&A session, we will have Johan and Iris, our analysts from Redeye, to ask questions. But you could also, as a participant, submit questions using the form in the Teams application. And if I should move into the BioVica introduction, I'll start talking about our product Divitum. Divitum is a tool for measuring cell proliferation from a simple blood sample. And we do that by measuring an enzyme, which is closely related to the cell proliferation cycle. This has proven to have several advantages. when monitoring treatments for cancer patients, as cancer grows through cell proliferation, and it correlates both to before start of treatment, how aggressive the disease is, but also it provides quick feedback if the treatment is efficient or not, or if the treating physician needs to take action, change dose or change treatment. Currently these patients are monitored by using different types of image diagnostics primarily. And so we offer a complimentary tool that can more quickly provide feedback and also more convenient. This is of course very important, especially so for the patient and to get either a confirmation that she is on an effective treatment or can take action changing the treatment if it's not optimal. It's also important, as we will talk about further down the presentation, for the healthcare providers, as it has cost impacts. Th...